Pacific Biosciences of California (NASDAQ: PACB) and Viewray (NASDAQ:VRAY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.
Earnings and Valuation
This table compares Pacific Biosciences of California and Viewray’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pacific Biosciences of California||$90.71 million||3.40||-$74.37 million||($0.91)||-2.91|
|Viewray||$22.24 million||26.82||-$50.63 million||($1.13)||-7.81|
Institutional & Insider Ownership
70.5% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 50.0% of Viewray shares are owned by institutional investors. 17.8% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 62.8% of Viewray shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Pacific Biosciences of California has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Viewray has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.
This table compares Pacific Biosciences of California and Viewray’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacific Biosciences of California||-95.97%||-97.50%||-59.40%|
This is a summary of current ratings for Pacific Biosciences of California and Viewray, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacific Biosciences of California||0||2||1||0||2.33|
Pacific Biosciences of California currently has a consensus target price of $6.27, suggesting a potential upside of 136.48%. Viewray has a consensus target price of $11.20, suggesting a potential upside of 26.84%. Given Pacific Biosciences of California’s higher probable upside, research analysts clearly believe Pacific Biosciences of California is more favorable than Viewray.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.